One study demonstrated that inhibition of CSC-specific POSTN and its related pathways or the GBM derivative CCL5 disrupted CSC–TAM interaction in mouse models of GBM and prostate cancer [69,110]. This evidence concerns the gene CCL5 and prostate carcinoma.